Esperion Therapeutics (NASDAQ:ESPR) web site states that the company is a late-stage pharmaceutical company developing non-statin low density lipoprotein cholesterol-lowering (LDL-C) therapies. Three phase 3 studies are underway with nice preliminary results. LDLs are regarded as the harmful type of cholesterol when elevated levels are present. As described by the Center for Disease Control, LDL-C forms plaques that can build up in arteries and lead to heart disease and stroke. Bempedoic acid, its lead product, was confirmed by FDA in March 2017 to have an approval pathway and the company plans to submit its regulatory filings for manufacturing and NDA in the first half of 2019, pending readout of its global pivotal phase 3 trial expected in quarter two of 2018.
